Immune Checkpoint Blocking (ICB) Therapy Development

Are you struggling with cancer resistance and looking for an integrated solution to overcome it? Look no further than our unique Immune Checkpoint Blocking (ICB)-based therapy development services. If you are looking for a second opinion, exploring alternative therapies, or seeking a more personalized approach to your cancer treatment, Creative Biolabs is always here to help.

Introduction

Creative Biolabs is a top biotech company dedicated to revolutionizing cancer treatment through ICB therapy. We have developed a series of solutions that harness the power of the body's immune system to overcome cancer resistance. Nowadays, Creative Biolabs can provide ICB-based therapy development services to address cancer resistance. Our scientists are skilled in building customized ICB platforms that cater to the special needs of each client. For instance, we offer our customers a new approach that targets and eliminates cancer cells by blocking immune checkpoints that inhibit the body's natural defense mechanisms.

Nowadays, Creative Biolabs can provide ICB-based therapy development services to address cancer resistance. Our scientists are skilled in building customized ICB platforms that cater to the special needs of each client. With our advanced technology and expertise, we can effectively reverse cancer resistance and improve treatment outcomes.

Fig.1 ICB/ICI Therapy Mechanism.^1,3

Service Procedures

At Creative Biolabs, our services are designed to target molecules on immune cells to enhance their ability to recognize and attack cancer cells. Till now, we can provide a full range of ICB services including identifying and characterizing immune checkpoint proteins, studying their role in diseases such as cancer, developing therapies that target immune checkpoints, and assessing the effectiveness of immune checkpoint inhibitors. Our project data can help clients better understand the immune system and develop new cancer immunotherapies.

1. Identification of a potential target: The first step in the ICB-based therapy development process is to identify a target that is involved in the immune response to cancer.
2. Validation of the target: Once a potential target has been identified, we can confirm its role in cancer immunotherapy. Our solutions can involve in vitro and in vivo studies using different kinds of human or animal cancer models.
3. Drug screening and development: With a validated target in hand, Creative Biolabs can begin screening for potential drugs or compounds that can modulate the target and enhance the immune response to cancer.
4. Preclinical testing: We will test the drug in animal models of cancer to evaluate its pharmacokinetics, toxicity, \anti-tumor activity, and anticancer resistance mechanism.

Fig.2 Tumor Cells States Analysis in ICB Resistant Melanoma.^2,4

Why Choose Us?

• Comprehensive Analysis: Our team will conduct a thorough analysis of your cancer type, stage, and specific resistance mechanisms to ICB therapy.
• Customized Treatment Plan: Based on the analysis, we will develop a customized plan that combines ICB therapy with other targeted therapies or immunomodulators to overcome resistance.
• Monitoring and Adjustments: Throughout the project process, we will closely monitor the therapy response results and make adjustments as needed. This proactive approach will ensure that we are constantly optimizing the treatment plan to overcome resistance and achieve the best possible outcome.
• Data-driven decision-making: We will leverage this data to make evidence-based decisions and continuously improve our strategies for overcoming resistance.

We are confident that our services can help you overcome resistance to ICB therapy and improve your project data. Creative Biolabs looks forward to working with you to provide the best possible care and support throughout your overcoming cancer resistance journey. Please do not hesitate to contact us for inquiries.

References

1. Kumar, Sunil, et al. "Epitranscriptomic approach: To improve the efficacy of ICB therapy by Co-targeting intracellular checkpoint cish." Cells 10.9 (2021): 2250.
2. Lauss, Martin, et al. "Molecular patterns of resistance to immune checkpoint blockade in melanoma." Nature Communications 15.1 (2024): 3075.
3. Image retrieved from Figure 2 "Mechanism of immune checkpoint blockage or inhibition (ICB/ICI) therapy." Kumar et al., 2021, used under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). The title was changed to " ICB/ICI Therapy Mechanism."
4. Image retrieved from Figure 3 "Tumor cells states in immune checkpoint blockade (ICB) resistant melanoma." Lauss et al., 2024, used under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). The title was changed to "Tumor Cells States Analysis in ICB Resistant Melanoma."

For Research Use Only | Not For Clinical Use